KEAP1 and non-small cell lung carcinoma: Additionally, elevated Nrf2 expression is associated with poor prognosis in non-small cell lung cancer (NSCLC), and the activation status of Nrf2 in KEAP1-mutant lung cancer patients serves as a predictor of tumor sensitivity to antioxidant therapies [361,362].